NasdaqGM:AQST

Stock Analysis Report

Executive Summary

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs.

Snowflake

Fundamentals

High growth potential and slightly overvalued.

Risks

  • Aquestive Therapeutics has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Aquestive Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.8%

NasdaqGM:AQST

-1.8%

US Pharmaceuticals

-1.0%

US Market


1 Year Return

-76.2%

NasdaqGM:AQST

-6.6%

US Pharmaceuticals

-0.4%

US Market

AQST underperformed the Pharmaceuticals industry which returned -6.8% over the past year.

AQST underperformed the Market in United States of America which returned -1.7% over the past year.


Share holder returns

AQSTIndustryMarket
7 Day-0.8%-1.8%-1.0%
30 Day-7.5%-3.1%-3.3%
90 Day-24.6%-3.9%0.4%
1 Year-76.2%-76.2%-4.3%-6.6%1.8%-0.4%
3 Yearn/a7.9%0.6%39.4%30.4%
5 Yearn/a22.9%10.0%54.2%37.1%

Price Volatility Vs. Market

How volatile is Aquestive Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aquestive Therapeutics undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Aquestive Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).

Aquestive Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Aquestive Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Aquestive Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Aquestive Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Aquestive Therapeutics has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Aquestive Therapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

67.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Aquestive Therapeutics's revenue is expected to grow significantly at over 20% yearly.

Aquestive Therapeutics's earnings are expected to grow significantly at over 20% yearly.

Aquestive Therapeutics's revenue growth is expected to exceed the United States of America market average.

Aquestive Therapeutics's earnings growth is expected to exceed the United States of America market average.

Aquestive Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Aquestive Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Aquestive Therapeutics performed over the past 5 years?

-70.2%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Aquestive Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Aquestive Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Aquestive Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Aquestive Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Aquestive Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Aquestive Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Aquestive Therapeutics's financial position?


Financial Position Analysis

Aquestive Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Aquestive Therapeutics's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Aquestive Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Aquestive Therapeutics's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

Aquestive Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Aquestive Therapeutics has less than a year of cash runway based on current free cash flow.

Aquestive Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 94% each year.


Next Steps

Dividend

What is Aquestive Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Aquestive Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Aquestive Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Aquestive Therapeutics has not reported any payouts.

Unable to verify if Aquestive Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Aquestive Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Aquestive Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.6yrs

Average management tenure


CEO

Keith Kendall (61yo)

4.8yrs

Tenure

US$8,010,587

Compensation

Mr. Keith J. Kendall has been the Chief Executive Officer of MonoSol RX, Inc since December 17, 2014 and also serves as its President, Principal Accounting Officer, Secretary and Treasurer. Mr. Kendall ser ...


CEO Compensation Analysis

Keith's remuneration is higher than average for companies of similar size in United States of America.

Keith's compensation has increased whilst company is loss making.


Management Age and Tenure

3.6yrs

Average Tenure

58yo

Average Age

The tenure for the Aquestive Therapeutics management team is about average.


Board Age and Tenure

4.8yrs

Average Tenure

61yo

Average Age

The tenure for the Aquestive Therapeutics board of directors is about average.


Insider Trading

More shares have been bought than sold by Aquestive Therapeutics individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyUS$2,28613 Aug 19
Peter Boyd
EntityIndividual
Role
Senior Vice President of Business Process & Information Technology
Shares600
Max PriceUS$3.81
BuyUS$40,74713 Aug 19
Lori Braender
EntityIndividual
Shares10,000
Max PriceUS$4.07
BuyUS$3,99013 Aug 19
Theresa Wood
EntityIndividual
Role
Senior Vice President of Human Resources
Shares1,000
Max PriceUS$3.99
BuyUS$7,78011 Dec 18
Alexander Schobel
EntityIndividual
Role
Chief Innovation & Technology Officer
Shares1,000
Max PriceUS$7.78
BuyUS$17,38010 Dec 18
Alexander Schobel
EntityIndividual
Role
Chief Innovation & Technology Officer
Shares2,000
Max PriceUS$8.69
BuyUS$8,00010 Dec 18
Daniel Barber
EntityIndividual
Role
Senior VP & COO
Shares1,000
Max PriceUS$8.00
BuyUS$44,35007 Dec 18
John Maxwell
EntityIndividual
Role
Senior VP & CFO
Shares5,000
Max PriceUS$8.87
BuyUS$14,66703 Dec 18
Ken Marshall
EntityIndividual
Role
Senior VP & Chief Commercial Officer
Shares1,445
Max PriceUS$10.15
BuyUS$10,57029 Nov 18
Lori Braender
EntityIndividual
Shares1,000
Max PriceUS$10.57
BuyUS$9,87028 Nov 18
Keith Kendall
EntityIndividual
Role
CEO, President & Director
Member of the Board of Directors
Shares1,000
Max PriceUS$9.87
BuyUS$5,17026 Nov 18
Theresa Wood
EntityIndividual
Role
Senior Vice President of Human Resources
Shares500
Max PriceUS$10.34
BuyUS$10,25026 Nov 18
Alexander Schobel
EntityIndividual
Role
Chief Innovation & Technology Officer
Shares1,000
Max PriceUS$10.25
BuyUS$98,00026 Nov 18
John Maxwell
EntityIndividual
Role
Senior VP & CFO
Shares10,000
Max PriceUS$9.80
BuyUS$80,32526 Nov 18
Keith Kendall
EntityIndividual
Role
CEO, President & Director
Member of the Board of Directors
Shares7,950
Max PriceUS$10.17
BuyUS$1,99626 Nov 18
Peter Boyd
EntityIndividual
Role
Senior Vice President of Business Process & Information Technology
Shares200
Max PriceUS$9.98

Ownership Breakdown


Management Team

  • Keith Kendall (61yo)

    CEO, President & Director

    • Tenure: 4.8yrs
    • Compensation: $8.01m
  • John Maxwell (54yo)

    Senior VP & CFO

    • Tenure: 2.6yrs
    • Compensation: $1.89m
  • Ken Marshall (60yo)

    Senior VP & Chief Commercial Officer

    • Tenure: 1.6yrs
  • Peter Boyd (53yo)

    Senior Vice President of Business Process & Information Technology

  • Theresa Wood (56yo)

    Senior Vice President of Human Resources

    • Tenure: 12.9yrs
  • Lauren Walrath

    Head of Corporate Marketing & Communications

  • Eric Dadey

    Senior Vice-President of Research and Development

    • Tenure: 9.2yrs
  • Dan Barber (43yo)

    Senior VP & COO

    • Tenure: 0.3yrs
    • Compensation: $2.11m
  • Lori Braender (63yo)

    Senior VP

    • Tenure: 0.9yrs
  • Alexander Schobel (60yo)

    Chief Innovation & Technology Officer

    • Tenure: 4.7yrs
    • Compensation: $7.58m

Board Members

  • Sandy Costa (73yo)

    Chairman

    • Tenure: 1.0yrs
    • Compensation: $388.61k
  • Nancy Lurker (62yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: $312.69k
  • Greg Brown (65yo)

    Director

    • Tenure: 12.4yrs
    • Compensation: $447.78k
  • Jim Scibetta (54yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: $356.34k
  • Doug Bratton (60yo)

    Director

    • Tenure: 15.6yrs
    • Compensation: $451.28k
  • John Cochran (53yo)

    Director

    • Tenure: 15.6yrs
    • Compensation: $446.28k
  • Keith Kendall (61yo)

    CEO, President & Director

    • Tenure: 4.8yrs
    • Compensation: $8.01m

Company Information

Aquestive Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aquestive Therapeutics, Inc.
  • Ticker: AQST
  • Exchange: NasdaqGM
  • Founded: 2004
  • Industry: pharmaceuticals
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$95.351m
  • Shares outstanding: 25.03m
  • Website: Click here

Number of Employees


Location

  • Aquestive Therapeutics, Inc.
  • 30 Technology Drive
  • Warren
  • New Jersey
  • 7059
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AQSTNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 2018

Biography

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an o ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/17 00:50
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.